

# CITATION REPORT

List of articles citing

## Gut microbiota and nonalcoholic fatty liver disease

DOI: 10.1016/s1665-2681(19)31457-7  
Annals of Hepatology, 2012, 11, 440-449.

**Source:** <https://exaly.com/paper-pdf/54095476/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
123	Human intestinal metagenomics: state of the art and future. <b>2013</b> , 16, 232-9		46
122	Alterations in the redox state and liver damage: hints from the EASL Basic School of Hepatology. <b>2013</b> , 58, 365-74		40
121	The gut microbiota and the liver. Pathophysiological and clinical implications. <b>2013</b> , 58, 1020-7		85
120	Microbiota in health and irritable bowel syndrome: current knowledge, perspectives and therapeutic options. <b>2013</b> , 48, 995-1009		54
119	Mechanisms of liver involvement in systemic disease. <b>2013</b> , 27, 471-83		21
118	Gut microbiota and non-alcoholic fatty liver disease: new insights. <b>2013</b> , 19, 338-48		157
117	Pharmacological agents for nonalcoholic steatohepatitis. <b>2013</b> , 7 Suppl 2, 833-41		2
116	Liver Injury and the Activation of the Hepatic Myofibroblasts. <b>2013</b> , 1, 215-223		35
115	The gut microbiota and the liver: implications for clinical practice. <b>2013</b> , 7, 723-32		15
114	From NAFLD in clinical practice to answers from guidelines. <b>2013</b> , 59, 859-71		249
113	New food safety concerns associated with gut microbiota. <b>2013</b> , 34, 62-66		5
112	Systems biology of adipose tissue metabolism: regulation of growth, signaling and inflammation. <b>2013</b> , 5, 425-47		30
111	Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae. <b>2013</b> , 27, 195-208		52
110	Intestinal epithelial barrier function in liver cirrhosis: an extensive review of the literature. <b>2013</b> , 33, 1457-69		73
109	[Gut microbiota in health and disease]. <b>2013</b> , 78, 240-8		40
108	Gut microbiota in health and disease. <b>2013</b> , 78, 240-248		5
107	In vitro and in vivo models of non-alcoholic fatty liver disease (NAFLD). <b>2013</b> , 14, 11963-80		166

106	Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance. <b>2013</b> , 4, 223-31		106
105	Lipotoxicity: effects of dietary saturated and transfatty acids. <b>2013</b> , 2013, 137579		108
104	The role of gut microbiota in nutritional status. <b>2013</b> , 16, 509-16		19
103	Current world literature. Genes and cell metabolism. <b>2013</b> , 16, 485-92		
102	What does irritable bowel syndrome share with non-alcoholic fatty liver disease?. <b>2013</b> , 19, 5402-20		15
101	Gut microbiota and clinical disease: obesity and nonalcoholic Fatty liver disease. <b>2013</b> , 16, 22-7		35
100	Gut microbiota, probiotics, and human health. <b>2013</b> , 32, 81-91		24
99	Probiotics: a possible role in treatment of adult and pediatric non alcoholic fatty liver disease. <i>Annals of Hepatology</i> , <b>2013</b> , 12, 161-163	3.1	9
98	Probiotics in non-alcoholic fatty liver disease: which and when. <i>Annals of Hepatology</i> , <b>2013</b> , 12, 357-363	3.1	27
97	Non-alcoholic fatty liver disease: what the clinician needs to know. <b>2014</b> , 20, 12956-80		117
96	Nonalcoholic Fatty Liver Disease (NAFLD), a Manifestation of the Metabolic Syndrome: New Perspectives on the Nutritional Therapy. <b>2014</b> , 03,		2
95	The metabolic syndrome and chronic liver disease. <b>2014</b> , 20, 5010-24		27
94	Obesity, fatty liver disease and intestinal microbiota. <b>2014</b> , 20, 16452-63		109
93	Probiotics and synbiotics may improve liver aminotransferases levels in non-alcoholic fatty liver disease patients. <i>Annals of Hepatology</i> , <b>2014</b> , 13, 482-488	3.1	30
92	Changes in Gut Microbiota May Be Early Signs of Liver Toxicity Induced by Epoxiconazole in Rats. <b>2014</b> , 60, 135-142		30
91	Meta-omic platforms to assist in the understanding of NAFLD gut microbiota alterations: tools and applications. <b>2014</b> , 15, 684-711		21
90	Endoplasmic reticulum stress in hepatic steatosis and inflammatory bowel diseases. <b>2014</b> , 5, 242		49
89	Probiotics to Treat Visceral Obesity and Related Liver Disease. <b>2014</b> , 363-380		1

88	4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine-recommendations for facing obesity, fatty liver and fibrosis epidemics. <b>2014</b> , 5, 21		24
87	Gut microbiota and bile acids: an old story revisited (again). <b>2014</b> , 38, 129-31		6
86	Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity. <b>2014</b> , 46, 556-60		115
85	Effect of aerobic exercise and low carbohydrate diet on pre-diabetic non-alcoholic fatty liver disease in postmenopausal women and middle aged men--the role of gut microbiota composition: study protocol for the AELC randomized controlled trial. <b>2014</b> , 14, 48		24
84	Integrative Weight Management. <b>2014</b> ,		2
83	Introduction to Integrative Weight Management. <b>2014</b> , 1-8		0
82	The Human Gut Microbiome and Its Role in Obesity and the Metabolic Syndrome. <b>2014</b> , 71-105		4
81	Revisiting the metabolic syndrome and paving the way for microRNAs in non-alcoholic fatty liver disease. <i>FEBS Journal</i> , <b>2014</b> , 281, 2503-24	5-7	46
80	Coacervate whey protein improves inflammatory milieu in mice fed with high-fat diet. <b>2014</b> , 11, 15		3
79	Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. <b>2014</b> , 2, 901-10		634
78	Prevalence of nonalcoholic fatty liver disease and its metabolic risk factors in women of different ages and body mass index. <b>2015</b> , 22, 667-73		27
77	Naturally Occurring Stilbenoid TSG Reverses Non-Alcoholic Fatty Liver Diseases via Gut-Liver Axis. <i>PLoS ONE</i> , <b>2015</b> , 10, e0140346	3-7	30
76	Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. <b>2015</b> , 91, 1-9		158
75	Lactobacillus paracasei Induces M2-Dominant Kupffer Cell Polarization in a Mouse Model of Nonalcoholic Steatohepatitis. <b>2015</b> , 60, 3340-50		34
74	Pathophysiology of Liver Fibrosis. <b>2015</b> , 33, 492-7		82
73	Pathogenesis and Evolution of Liver Fibrosis: Cirrhosis or Cirrhoses?. <b>2015</b> , 3-12		1
72	Pathogenesis of nonalcoholic fatty liver disease (NAFLD). <b>2015</b> , 281-291		1
71	The Gut Microbiota and Nonalcoholic Fatty Liver Disease. <b>2015</b> , 35, 262-9		30

70	Sugar sweetened beverages and fatty liver disease: Rising concern and call to action. <b>2015</b> , 63, 306-8	3
69	Expression of toll-like receptors 1-5 but not TLR 6-10 is elevated in livers of patients with non-alcoholic fatty liver disease. <b>2015</b> , 35, 562-8	36
68	Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. <b>2015</b> , 47, 181-90	430
67	The intestinal microbiota and microenvironment in liver. <b>2015</b> , 14, 183-91	39
66	8. Mikrobiom und Lebererkrankungen. <b>2016</b> ,	2
65	Associations between White Blood Cell Count and the Development of Incidental Nonalcoholic Fatty Liver Disease. <b>2016</b> , 2016, 7653689	15
64	Ethanol Production by Selected Intestinal Microorganisms and Lactic Acid Bacteria Growing under Different Nutritional Conditions. <b>2016</b> , 7, 47	64
63	The Metabolic Role of the Microbiome: Implications for NAFLD and the Metabolic Syndrome. <b>2016</b> , 36, 312-316	16
62	Hypogonadism alters cecal and fecal microbiota in male mice. <b>2016</b> , 7, 533-539	33
61	Microbiota Modulation With Synbiotic Decreases Liver Fibrosis in a High Fat Choline Deficient Diet Mice Model of Non-Alcoholic Steatohepatitis (NASH). <b>2016</b> , 23, 132-141	16
60	Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis?. <b>2016</b> , 51, 211-21	53
59	A "systems medicine" approach to the study of non-alcoholic fatty liver disease. <b>2016</b> , 48, 333-42	42
58	Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis. <b>2016</b> , 51, 162-72	25
57	Small Intestinal Bacterial Overgrowth. <b>2016</b> , 487-494	
56	Commensal bacteria at the crossroad between cholesterol homeostasis and chronic inflammation in atherosclerosis. <b>2017</b> , 58, 519-528	67
55	Probiotics for people with hepatic encephalopathy. <b>2017</b> , 2, CD008716	48
54	Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification. <b>2017</b> , 49, 385-399	18
53	Health relevance of the modification of low grade inflammation in ageing (inflammageing) and the role of nutrition. <b>2017</b> , 40, 95-119	221

52	Serum ferritin as a non-invasive marker in the prediction of hepatic fibrosis among Egyptian patients with non-alcoholic fatty liver disease. <b>2017</b> , 1, 112-119		4
51	Intestinal gas and liver steatosis: a casual association? A prospective multicentre assessment. <b>2017</b> , 37, 141-147		0
50	Impact of Time-Restricted Feeding and Dawn-to-Sunset Fasting on Circadian Rhythm, Obesity, Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease. <b>2017</b> , 2017, 3932491		23
49	Liver fibrosis: the 2017 state of art. <b>2017</b> , 59, 320-331		35
48	Oxidative Stress and Gut Microbiota. <b>2017</b> , 113-123		6
47	Serum testosterone and non-alcoholic fatty liver disease in men and women in the US. <b>2018</b> , 38, 2051-2059		36
46	Metabolomic Signatures and Metabolic Complications in Childhood Obesity. <b>2018</b> , 343-361		4
45	Actinobacteria: A relevant minority for the maintenance of gut homeostasis. <b>2018</b> , 50, 421-428		158
44	The gut-liver axis: impact of a mouse model of small-bowel bacterial overgrowth. <b>2018</b> , 221, 246-256		3
43	An overview on the interplay between nutraceuticals and gut microbiota. <b>2018</b> , 6, e4465		17
42	Maternal consumption of green tea extract during pregnancy and lactation alters offspring's metabolism in rats. <i>PLoS ONE</i> , <b>2018</b> , 13, e0199969	3.7	8
41	Linking the gut and liver: crosstalk between regulatory T cells and mucosa-associated invariant T cells. <b>2018</b> , 12, 305-314		13
40	Hepatic Steatosis-a complex interaction of germs, genes and grub. <b>2018</b> , 84, 475-476		
39	Volatile Oil of Inhibits Nonalcoholic Fatty Liver Disease via the Gut-Liver Axis. <b>2018</b> , 2018, 3589874		10
38	Effect of Kombucha on gut-microbiota in mouse having non-alcoholic fatty liver disease. <b>2019</b> , 28, 261-267		22
37	FATTY LIVER AND GUT MICROBIOTA: A NEW MULTI-DIMENSIONAL APPROACH FOR PERSONALIZED PREVENTIVE MEDICINE. <b>2019</b> , 10,		
36	Overview of the Pathogenesis, Genetic, and Non-Invasive Clinical, Biochemical, and Scoring Methods in the Assessment of NAFLD. <b>2019</b> , 16,		15
35	Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH). <i>Annals of Hepatology</i> , <b>2019</b> , 18, 416-421	3.1	28

34	Characterization and comparisons of microbiota in different intestinal segments between adult Chinese Shanxi Black Pigs and Large White Pigs. <b>2019</b> , 69, 447-456		3
33	Intestinally derived bacterial products stimulate development of nonalcoholic steatohepatitis. <b>2019</b> , 141, 418-428		7
32	Yes-Associated Protein in Kupffer Cells Enhances the Production of Proinflammatory Cytokines and Promotes the Development of Nonalcoholic Steatohepatitis. <b>2020</b> , 72, 72-87		23
31	Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis. <b>2020</b> , 21,		8
30	Gut Microbiota between Environment and Genetic Background in Familial Mediterranean Fever (FMF). <b>2020</b> , 11,		6
29	Effects of MP Polyethylene Microparticles on Microbiome and Inflammatory Response of Larval Zebrafish. <b>2020</b> , 8,		11
28	Effects of polysaccharide from Pueraria lobata on gut microbiota in mice. <b>2020</b> , 158, 740-740		12
27	Pathobiological and molecular connections involved in the high fructose and high fat diet induced diabetes associated nonalcoholic fatty liver disease. <b>2020</b> , 69, 851-867		2
26	Endotoxin Producers Overgrowing in Human Gut Microbiota as the Causative Agents for Nonalcoholic Fatty Liver Disease. <b>2020</b> , 11,		48
25	Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: An emerging paradigm. <b>2020</b> , 39, 9-21		18
24	Nonalcoholic fatty liver disease and risk of prostatic diseases: Roles of insulin resistance. <b>2021</b> , 53, e14060	o	
23	Effects of betaine on non-alcoholic liver disease. <i>Nutrition Research Reviews</i> , <b>2021</b> , 1-11	7	o
22	Probiotics-rich emulsion improves insulin signalling in Palmitate/Oleate-challenged human hepatocarcinoma cells through the modulation of Fetuin-A/TLR4-JNK-NF- $\kappa$ B pathway. <i>Biomedicine and Pharmacotherapy</i> , <b>2021</b> , 139, 111560	7.5	6
21	Pathogenesis of Nonalcoholic Fatty Liver Disease. <b>2018</b> , 369-390.e14		1
20	Microbiota, NASH, HCC and the potential role of probiotics. <i>Carcinogenesis</i> , <b>2017</b> , 38, 231-240	4.6	113
19	Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice. <i>PLoS ONE</i> , <b>2014</b> , 9, e80169	3.7	168
18	An assessment of bacterial overgrowth and translocation in the non-alcoholic fatty liver of patients with morbid obesity. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2019</b> , 111, 294-300	0.9	3
17	Influence of the Intestinal Microbiota on Diabetes Management. <i>Current Pharmaceutical Biotechnology</i> , <b>2020</b> , 21, 1603-1615	2.6	2

16	Nonalcoholic Fatty Liver Disease Is Associated with Benign Prostate Hyperplasia. <i>Journal of Korean Medical Science</i> , <b>2020</b> , 35, e164	4.7	2
15	The Effect of Synbiotic Supplementation on Body Composition and Lipid Profile in Patients with NAFLD: A Randomized, Double Blind, Placebo-Controlled Clinical Trial Study. <i>Iranian Red Crescent Medical Journal</i> , <b>2017</b> , 19,	1.3	10
14	The Effect of Probiotic and/or Prebiotic on Liver Function Tests in Patients with Nonalcoholic Fatty Liver Disease: A Double Blind Randomized Clinical Trial. <i>Iranian Red Crescent Medical Journal</i> , <b>2017</b> , 19,	1.3	19
13	Gut microbiota: A potential therapeutic target for management of diabetic retinopathy?. <i>Life Sciences</i> , <b>2021</b> , 286, 120060	6.8	0
12	THE EFFICACY OF ERADICATION OF SMALL INTESTINAL BACTERIAL OVERGROWTH IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE. <i>EUREKA Health Sciences</i> , <b>2017</b> , 4, 34-41	0.1	0
11	The Microbiota-Gut-Liver Axis: Implications for the Pathophysiology of Liver Disease. <b>2020</b> , 125-137		
10	Comparative analysis of the composition of intestinal microbiome in patients with liver diseases. <i>ScienceRise Biological Science</i> , <b>2020</b> , 15-22	0.1	
9	Progressive Liver Fibrosis in Non-Alcoholic Fatty Liver Disease.. <i>Cells</i> , <b>2021</b> , 10,	7.9	1
8	The possible protective role of N-acetyl cysteine on duodenal mucosa of high fat diet and orlistat treated adult male albino rats and the active role of tumor necrosis factor (TNF) and Interleukin 6 (IL6) (histological and biochemical study).. <i>Ultrastructural Pathology</i> , <b>2022</b> , 1-19	1.3	1
7	Gut microbiota and butyrate contribute to nonalcoholic fatty liver disease in premenopause due to estrogen deficiency.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0262855	3.7	1
6	The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. <i>Terapevticheskii Arkhiv</i> , <b>2022</b> , 94, 216-253	0.9	5
5	Emerging roles of the Hippo signaling pathway in modulating immune response and inflammation-driven tissue repair and remodeling.. <i>FEBS Journal</i> , <b>2022</b> ,	5.7	0
4	Microbial personified therapy as an instrument of medical doctor in the future. <b>2022</b> , 2, 51-62		
3	Extrahepatic factors in hepatic immune regulation. 13,		0
2	Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease. <b>2022</b> , 32, 104-140		1
1	Gut Microbiota: A Future Clinical Magic Bullet to Manifest Pathogenic Disease in the Current Future. <b>2023</b> , 17, 51-68		0